Sheel Biotech IPO Lists at ₹91 on NSE Emerge, Surges 51% to ₹95.55 on Debut

New Delhi, October 8, 2025 – Sheel Biotech Limited IPO (NSE Emerge: SHEEL) had a successful debut on the NSE Emerge platform with its stock listing at ₹91 per share, an impressive premium of 44.4% over the issue price of ₹63. On its first trading day, the price jumped to an intraday high of ₹95.55, 51.6% higher than the issue price.

Sheel Biotech was formed in 1991, as a subsidiary of the Escort Group company, and is a manufacturer of tissue culture, organic farming, greenhouse formation & and landscaping. Sheel Biotech also has a state-of-the-art research and development (R&D) centre, with the ability to produce 10 million plants, and collaborates with government and private organisations across India.

Sheel Biotech IPO Market Reaction

It was trading at 1:00 p.m. IST, 51.67 per cent higher than the opening price of ₹91.00. Its highest trading point is ₹95.55, and the lowest point is ₹91.00, thus far. The total number of shares that have changed hands is 27.08 lakh, and the total market capitalisation is 194.47 crore.

Sheel Biotech IPO Strong Investor Demand On Listing Day

The counter commenced trading with a significant amount of buying, demonstrating strong investor preference. A buy quantity of 4.54 lakh shares was recorded versus only 16,000 shares sold, reflecting positive sentiment. A total of ₹24.84 crore traded value was reported as investors continued to show interest following a strong IPO subscription.

Sheel Biotech IPO Anchor Investors and Pre-IPO Funding

Before the IPO, on September 29, 2025, Sheel Biotech raised ₹9.6 crore from anchor investors via the allocation of 15.24 lakh shares at ₹63/share. The anchor book comprised large funds, such as the Bharat Venture Opportunities Fund, Aarth AIF Growth Fund, Saint Capital Fund, VBCube Ventures Fund, and Sanshi Fund–1, signalling institutional belief in the company’s future growth.

Sheel Biotech IPO Subscription

The IPO, valued at ₹34 crore, was oversubscribed 14.93 times in total, including qualified institutional buyers, high-net-worth individuals, and retail investors. Working capital, capital expenditures, and corporate purposes will be funded through IPO proceeds.

Outlook

With its robust listing and promising growth potential in the sector, Sheel Biotech appears to be well-positioned to attract ongoing investor interest and achieve steady growth in India’s agri-biotech market.

REF: https://www.nseindia.com/get-quotes/equity?symbol=SHEEL

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations